TRISALUS LIFE SCIENCES INC (TLSI) Stock Price & Overview
NASDAQ:TLSI • US89680M1018
Current stock price
The current stock price of TLSI is 3.86 USD. Today TLSI is up by 0.26%. In the past month the price decreased by -16.27%. In the past year, price decreased by -31.56%.
TLSI Key Statistics
- Market Cap
- 230.867M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.12
- Dividend Yield
- N/A
TLSI Stock Performance
TLSI Stock Chart
TLSI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to TLSI. When comparing the yearly performance of all stocks, TLSI is a bad performer in the overall market: 92.07% of all stocks are doing better.
TLSI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TLSI. Both the profitability and financial health of TLSI have multiple concerns.
TLSI Earnings
On January 12, 2026 TLSI reported an EPS of -0.21 and a revenue of 13.21M. The company missed EPS expectations (-56.36% surprise) and beat revenue expectations (2.08% surprise).
TLSI Forecast & Estimates
13 analysts have analysed TLSI and the average price target is 11.73 USD. This implies a price increase of 203.89% is expected in the next year compared to the current price of 3.86.
For the next year, analysts expect an EPS growth of 77.96% and a revenue growth 40.05% for TLSI
TLSI Groups
Sector & Classification
TLSI Financial Highlights
Over the last trailing twelve months TLSI reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS increased by 15.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -201.28% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TLSI Ownership
TLSI Latest News, Press Relases and Analysis
TLSI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.9 | 368.381B | ||
| AMGN | AMGEN INC | 15.33 | 189.472B | ||
| GILD | GILEAD SCIENCES INC | 15.96 | 175.4B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.63 | 114.717B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.77 | 78.668B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.7 | 41.749B | ||
| INSM | INSMED INC | N/A | 30.759B | ||
| NTRA | NATERA INC | N/A | 28.033B | ||
| BIIB | BIOGEN INC | 11.41 | 26.756B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.64 | 23.245B | ||
| MRNA | MODERNA INC | N/A | 20.695B | ||
| EXAS | EXACT SCIENCES CORP | 341.89 | 19.805B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.443B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TLSI
Company Profile
TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. The firm is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
Company Info
IPO: 2020-12-18
TRISALUS LIFE SCIENCES INC
6272 W. 91st Ave.
Westminster COLORADO US
Employees: 110
Phone: 14153368917
TRISALUS LIFE SCIENCES INC / TLSI FAQ
What does TLSI do?
TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. The firm is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
What is the stock price of TRISALUS LIFE SCIENCES INC today?
The current stock price of TLSI is 3.86 USD. The price increased by 0.26% in the last trading session.
Does TLSI stock pay dividends?
TLSI does not pay a dividend.
What is the ChartMill rating of TRISALUS LIFE SCIENCES INC stock?
TLSI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for TRISALUS LIFE SCIENCES INC?
TRISALUS LIFE SCIENCES INC (TLSI) operates in the Health Care sector and the Biotechnology industry.
What is the expected growth for TLSI stock?
The Revenue of TRISALUS LIFE SCIENCES INC (TLSI) is expected to grow by 40.05% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is TRISALUS LIFE SCIENCES INC worth?
TRISALUS LIFE SCIENCES INC (TLSI) has a market capitalization of 230.87M USD. This makes TLSI a Micro Cap stock.